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Background: RNA interference (RNAi) is a powerful approach in functional genomics to selectively silence
messenger mRNA (mRNA) expression and can be employed to rapidly develop potential novel drugs against a
complex disease like cancer. However, naked siRNA being anionic is unable to cross the anionic cell membrane
through passive diffusion and therefore, delivery of siRNA remains a major hurdle to overcome before the potential
of siRNA technology can fully be exploited in cancer. pH-sensitive carbonate apatite has recently been developed
as an efficient tool to deliver siRNA into the mammalian cells by virtue of its high affinity interaction with the siRNA
and the desirable size distribution of the resulting siRNA-apatite complex for effective cellular endocytosis.
Moreover, internalized siRNA was found to escape from the endosomes in a time-dependent manner and
efficiently silence gene expression.
Results: Here we show that carbonate apatite-mediated delivery of siRNA against PLC-gamma-2 (PLCG2) and
calmodulin 1 (CALM1) genes has led to the sensitization of a human cervical cancer cell line to doxorubicin- and
paclitaxel depending on the dosage of the individual drug whereas no such enhancement in cell death was
observed with cisplatin irrespective of the dosage following intracellular delivery of the siRNAs.
Conclusion: Thus, PLCG2 and CALM1 genes are two potential targets for gene knockdown in doxorubicin and
paclitaxel-based chemotherapy of cervical cancer.
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Genes are transcribed into mRNAs and subsequently
translated into proteins to carry out the major functions
within a cell and the mutations in certain genes leading
to their suppression or overexpression are usually re-
sponsible for both acquired and genetic diseases. Deliv-
ery of functional gene(s) or gene-silencing element(s)
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reproduction in any medium, provided the orfunctions of the cell. RNA interference (RNAi) that can
selectively silence mRNA expression in cell cytoplasm
can be utilized to develop new drugs against target
therapeutic genes [1-5]. RNAi can be harnessed for se-
lective gene inhibition in two different routes: 1) cyto-
plasmic delivery of short interfering RNA (siRNA) for
directly breaking down the specific mRNA and 2) nu-
clear delivery of gene expression cassettes to express a
short hairpin RNA (shRNA) which is further processed
by cellular machinery to siRNA in the cytoplasm [6].
However, siRNA, a synthetic RNA duplex of 21–23
nucleotides, is more advantageous than shRNA because
of the difficulty in the construction of a shRNA expres-
sion system [6], and the requirement of the expression
system to overcome the nuclear barrier for shRNAral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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incorporates into a multiprotein RNA-induced silencing
complex (RISC) and is unwound into single-stranded
RNAs by Argonaute 2, a multifunctional protein within
the RISC, forming antisense strand-associated RISC in
order to guide and selectively degrade the complemen-
tary mRNA with the help of Argonaute-2 [8]. Perfect
hybridization between the antisense strand of siRNA
and the target mRNA leads to degradation of the mRNA
near the center of the target-siRNA duplex [8]. However,
the strong anionic phosphate backbone with consequen-
tial electrostatic repulsion from the anionic cell mem-
brane is an obstacle to the passive diffusion of siRNA
across the membrane [9]. The hydrophobic lipid bilayer
could pose an additional barrier to the hydrophilic
siRNA. Moreover, naked siRNA can be degraded by the
plasma nucleases and even subjected to renal elimin-
ation due to its small size before reaching the target site
in vivo [10,11]. A number of existing non-viral vectors
have been developed for intracellular siRNA delivery
with limited efficacy [8]. Usually, a non-viral vector
being cationic can electrostatically bind with an anionic
siRNA to form a stable complex, thus protecting it from
nuclease-mediated degradation, enabling it to cross the
plasma membrane through endocytosis and finally facili-
tating its endosomal escape [8].
Cancer is a complex disease responsible for millions of
deaths worldwide and despite remarkable efforts made
in the last decades limited successes have been achieved
so far to cure various types of cancer. Clinical efficacy of
current chemotherapeutic drugs are often limited owing
to to their toxic effects on normal cells and the patients
can tolerate only the doses which are therapeutically in-
sufficient, thus leading to chemoresistance and subse-
quent tumor recurrence [12]. Since cancer is the result
of overexpression or suppression of signaling pathways
aiding cancer cell survival and proliferation, non-viral
vector-mediated delivery of siRNAs specific for the
genes of pathways, to cancer cells would be the potential
treatment options that might additionally render cancer
cells extremely sensitive to cytotoxic chemotherapy [11].
Among the signalling cascades, MAP kinase, PI-3 knase
and Ca2+-calmodulin pathways are extensively involved
in proliferation and survival of various cancer cells [13-
15]. On the other hand, conventionally used chemother-
apy drugs induce apoptosis of cancer cells by interfering
with the major cellular functions which might have some
of cross-talk with the components of cell proliferation/
survival pathways. siRNA-mediated knock-down of the
genes encoding the enzymes of those pathways, there-
fore, might not only slow down the growth of cancer
cells, but also sensitize them to anti-cancer drugs.
In Ca2+-calmodulin pathway, stimulation with growth
factor either G protein-coupled receptors or receptortyrosine kinases activates the phospholipase C (PLC) en-
zyme, which, in turn, hydrolyses the membrane
phospholipid, phosphatidylinositol 4, 5 bisphosphate
(PIP2) to diacylglycerol (DAG) and inositol (1,4,5) tri-
sphosphate (IP3). DAG activates PKC while IP3 binds to
its receptor on the endoplasmic reticulum allowing dif-
fusion of Ca2+ from the ER to increase intracellular
[Ca2+] [16]. The released Ca2+ binds to calmodulin
(CaM) and Ca2+/CaM functions as an allosteric activator
of a considerable number of protein kinases regulating
cell proliferation and apoptosis [17].
Recently, we have developed an efficient siRNA deliv-
ery system based on some unique properties of carbon-
ate apatite- electrostatic affinity for binding anionic
siRNA, ability of preventing crystal growth for gener-
ation of nano-size particles for efficient endocytosis and
fast dissolution kinetics in endosomal acidic compart-
ments to facilitate the release of siRNA from the parti-
cles as well as from the endosomes, leading to the
efficient silencing of reporter gene expression. Moreover,
nanoparticle-assisted delivery of validated siRNA against
cyclin B1 resulted in the significant inhibition of cancer
cell growth [18,19].
Here we show that carbonate apatite-mediated delivery
of siRNA against PLC-gamma-2 (PLCG2) and calmodu-
lin 1 (CALM1) genes sensitized a human cervical cancer
cell line (HeLa cell) to doxorubicin- and paclitaxel-
induced cell death depending on the doses of the drugs
while no such synergistic effect was observed with cis-
platin, another commonly used chemotherapy drugs.
Results and discussion
Roles of PLCG2 and CALM1 in the proliferation/survival of
cervical cancer cells
In order to investigate the potential roles of PLCG2 and
CALM1 in the proliferation or survival of HeLa cells
that express both of the proteins [20-23], specific vali-
dated siRNA (10 mM) against PLCG2 or CALM1
mRNA was added together with Ca2+ (3 mM) to the bi-
carbonate-buffered DMEM prior to the incubation at
37 °C for 30 min to form carbonate apatite/siRNA com-
plexes. Figure 1 shows the cell viability as assessed by
MTT assay following consecutive 48 h incubation of
HeLa cells with the apatite complexes carrying either
anti-PLCG2 or anti-CALM1 siRNA. Almost 10% of the
cells were killed due to the silencing of either PLCG2 or
CALM1 gene expression indicating that PLCG2, an up-
stream molecule and CALM1, a downstream molecule
of Ca2+-calmodulin pathway are critically involved in the
proliferation or survival of HeLa cells.
While both of the siRNAs were validated by the manu-
facturer (QIAGEN) using quantitative RT-PCR to con-
firm their knockdown efficiency of 82%, the relatively
low efficacy of either treatment in killing cancer cells as
Figure 1 Effects of silencing of PLCG2 and CALM1 expression on cancer cell viability. 50,000 of HeLa cells from the exponentially growth
phase were seeded in each of the wells of a 24-well plates the day before the siRNA/apatite complexes were prepared by mixing 3 μl of 1 M
CaCl2 with 10 nM of siRNA in 1 ml of fresh serum-free HCO3
- (44 mM)-buffered DMEM medium (pH 7.5) and incubating at 37 °C for 30 min. The
medium containing the siRNA/apatite complexes supplemented with 10% FBS had been added onto the rinsed cells before the cells were
cultured consecutively for 48 h and the assessment on cell viability was carried out. Each experiment was done in triplicate and the data
represent mean value ± SE (n = 3).
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possibly due to the constitutive expression of the genes
in spite of the cleavage of substantial amount of the re-
spective mRNAs and the active roles being played by
MAP kinase and PI-3 kinase pathways in cell survival or
proliferation.Influences of PLCG2 and CALM1 gene knockdown on
cisplatin-induced cell toxicity
Cisplatin is one of the most effective anti-cancer drugs
for solid tumors, including ovarian, testicular, cervical,
and small cell lung cancers [24,25]. Treatment of HeLa
cells with 1 μM of cisplatin for 2 consecutive days
caused 25% of cell death compared with particles only
(Figure 2) and almost same level of cell death was
observed for the treatment where both apatite/siRNA
complexes and cisplatin were incubated together with
the cells for the same period of time, suggesting an addi-
tive effect on cell death probably owing to the lack of
cross-talk(s) between the pathways of Ca2+-calmodulin
signaling and cisplatin-mediated toxicity.
On the contrary, the combined treatment with apatite/
anti-PLCG2 siRNA complex and a lower dose of cis-
platin (200 nM) led to the enhancement of cell viability
compared with apatite/anti-PLCG2 siRNA or cisplatin
(Figure 3), indicating that cisplatin at that particular
dose might activate another form of PLC [26] or activate
MAP kinase/PI-3 kinase signaling cascades, leading to
the enhanced cell growth in the absence of PLCG2 . Si-
lencing of PLCG2 gene promoted more cell growth
than silencing of CALM1 gene at that lower dose of cis-
platin probably because PLCG2 is more upstream to
and therefore, more important regulator than CALM1
in Ca2+-calmodulin signaling.Influences of PLCG2 and CALM1 gene knockdown on
doxorubicin-induced cell toxicity
Doxorubicin is another chemotherapy drug widely used
for the treatment of a variety of cancers including cer-
vical cancer [27,28]. Doxorubicin which killed almost
50% of the cells at 1 μM concentration of the drug
(Figure 4) seems to be more potent than cisplatin which
killed 25% of the cells at the same dose (Figure 2) fol-
lowing continuous 2 day incubation with HeLa cells. Si-
lencing of PLCG2 gene following intracellular delivery of
apatite/anti-PLCG2 siRNA, clearly sensitized the cells to
doxorubicin at that particular concentration (1 μM) kill-
ing more than 60% of the cells due to the synergistic ef-
fect of the drug and the gene knockdown. This could be
due to the activation of Ca2+-calmodulin pathway [29]
by doxirubicin- an effect that might have hindered the
cytotoxic effect of doxorubicin and therefore, targeted
cleavage of PLC mRNA or to some extent calmodulin 1
mRNA resulted in blocking of the Ca-calmodulin
pathway and inhibition of cell growth or proliferation
(Figure 4), thus synergistically enhancing the cancer
cell apoptosis in presence of doxorubicin.
Similar finding was observed after intracellular delivery
of anti-PLCG2 siRNA and 200 nM of doxorubicin,
whereas delivery of anti-CALM1 siRNA did not result in
a synergistic effect in combination with doxorubicin
(200 nM) (Figure 5) probably because of CALM1 loca-
tion more downstream to PLCG2 in the pathway.
Influences of PLCG2 and CALM1 gene knockdown on
paclitaxel-induced cell toxicity
Paclitaxel as a microtubule stabilizer is used for the
treatment for various cancers including cervical cancer
in combination with cisplatin and other cancer drug(s)
[30,31]. As shown in Figures 6, 1 μM paclitaxel when
Figure 2 Effects of silencing of PLCG2 and CALM1 expression on viability of cancer cells under higher dose of cisplatin. 50,000 of HeLa
cells from the exponentially growth phase were seeded in each of the wells of a 24-well plates the day before the siRNA/apatite complexes were
prepared by mixing 3 μl of 1 M CaCl2 with 10 nM of siRNA in 1 ml of fresh serum-free HCO3- (44 mM)-buffered DMEM medium (pH 7.5) and
incubating at 37 °C for 30 min. The medium containing the siRNA/apatite complexes supplemented with 10% FBS had been added onto the
rinsed cells either with or without 1 μM of cisplatin before the cells were cultured consecutively for 48 h and the assessment on cell viability was
carried out. Each experiment was done in triplicate and the data represent mean value ± SE (n = 3).
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caused more than 70% of the cells to death, indicating
that paclitaxel is the most effective of the 3 drugs used
in the study. However, the combined treatment of the
apatite/siRNA complexes possessing either anti-PLCG2
or anti-CALM1 siRNA and paclitaxel (1 μM) resulted in
reduction of the total cell death by almost 10%. The
could be explained by the notion that silencing of theFigure 3 Effects of silencing of PLCG2 and CALM1 expression on viab
cells from the exponentially growth phase were seeded in each of the wel
prepared by mixing 3 μl of 1 M CaCl2 with 10 nM of siRNA in 1 ml of fresh
incubating at 37 °C for 30 min. The medium containing the siRNA/apatite c
rinsed cells either with or without 200 nM of cisplatin before the cells were
was carried out. Each experiment was done in triplicate and the data reprePLCG2 and CALM1 genes ends up with the down-
regulation of Ca2+/calmodulin signaling and the decline
in the level of Ca2+/calmodulin-dependent protein
kinases (CaMKs). Since CAMKs regulate microtubule
dynamics by phosphorylation of the microtubule regula-
tor stathmin [32], the overall effect of gene knockdown
might cause disruption of microtubule dynamics, thus
preventing paclitaxel to stabilize all of the microtubulesility of cancer cells under lower dose of cisplatin. 50,000 of HeLa
ls of a 24-well plates the day before the siRNA/apatite complexes were
serum-free HCO3
- (44 mM)-buffered DMEM medium (pH 7.5) and
omplexes supplemented with 10% FBS had been added onto the
cultured consecutively for 48 h and the assessment on cell viability
sent mean value ± SE (n = 3).
Figure 4 Effects of silencing of PLCG2 and CALM1 expression on viability of cancer cells under higher dose of doxorubicin. 50,000 of
HeLa cells from the exponentially growth phase were seeded in each of the wells of a 24-well plates the day before the siRNA/apatite complexes
were prepared by mixing 3 μl of 1 M CaCl2 with 10 nM of siRNA in 1 ml of fresh serum-free HCO3- (44 mM)-buffered DMEM medium (pH 7.5) and
incubating at 37 °C for 30 min. The medium containing the siRNA/apatite complexes supplemented with 10% FBS had been added onto the
rinsed cells either with or without 1 μM of doxorubicin before the cells were cultured consecutively for 48 h and the assessment on cell viability
was carried out. Each experiment was done in triplicate and the data represent mean value ± SE (n = 3).
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apoptosis at that relatively higher concentration of the
drug.
On the contrary, when the concentration of paclitaxel
was lowered to 200 nM, silencing of PLCG2 or CALM1
gene expression was associated with a robust decrease in
cell viability demonstrating a synergistic effect of the drugFigure 5 Effects of silencing of PLCG2 and CALM1 expression on viab
HeLa cells from the exponentially growth phase were seeded in each of th
were prepared by mixing 3 μl of 1 M CaCl2 with 10 nM of siRNA in 1 ml of
incubating at 37 °C for 30 min. The medium containing the siRNA/apatite c
rinsed cells either with or without 200 nM of doxorubicin before the cells w
viability was carried out. Each experiment was done in triplicate and the daaction and the gene knockdown on cell proliferation or
survival (Figure 7). Since Ca2+/CaM promotes cell prolif-
eration by facilitating G2/M transition, M phase progres-
sion, and exit from mitosis [15] while microtubules
induces apoptosis by arresting G2/M phase [33], silencing
of either PLCG2 or CALM1 gene in presence of paclitaxel
resulted in complete arrest of the cell cycle.ility of cancer cells under lower dose of doxorubicin. 50,000 of
e wells of a 24-well plates the day before the siRNA/apatite complexes
fresh serum-free HCO3
- (44 mM)-buffered DMEM medium (pH 7.5) and
omplexes supplemented with 10% FBS had been added onto the
ere cultured consecutively for 48 h and the assessment on cell
ta represent mean value ± SE (n = 3).
Figure 6 Effects of silencing of PLCG2 and CALM1 expression on viability of cancer cells under higher dose of paclitaxel. 50,000 of HeLa
cells from the exponentially growth phase were seeded in each of the wells of a 24-well plates the day before the siRNA/apatite complexes were
prepared by mixing 3 μl of 1 M CaCl2 with 10 nM of siRNA in 1 ml of fresh serum-free HCO3- (44 mM)-buffered DMEM medium (pH 7.5) and
incubating at 37 °C for 30 min. The medium containing the siRNA/apatite complexes supplemented with 10% FBS had been added onto the
rinsed cells either with or without 1 μM of paclitaxel before the cells were cultured consecutively for 48 h and the assessment on cell viability
was carried out. Each experiment was done in triplicate and the data represent mean value ± SE (n = 3).
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PLCG2 and CALM1 of Ca2+-calmodulin signalling path-
ways are the two potential targets for gene knockdown
in doxorubicin and paclitaxel-based chemotherapy ofFigure 7 Effects of silencing of PLCG2 and CALM1 expression on viab
cells from the exponentially growth phase were seeded in each of the wel
prepared by mixing 3 μl of 1 M CaCl2 with 10 nM of siRNA in 1 ml of fresh
incubating at 37 °C for 30 min. The medium containing the siRNA/apatite c
rinsed cells either with or without 200 nM of doxorubicin before the cells w
viability was carried out. Each experiment was done in triplicate and the dacervical cancer. Therefore, pre-clinical study in animal
models of cervical cancer should be carried out through
tumor-targeted delivery of anti-PLCG2 or CALM1 siRNA
in combination with passively diffusible anti-cancer drugs.ility of cancer cells under lower dose of paclitaxel. 50,000 of HeLa
ls of a 24-well plates the day before the siRNA/apatite complexes were
serum-free HCO3
- (44 mM)-buffered DMEM medium (pH 7.5) and
omplexes supplemented with 10% FBS had been added onto the
ere cultured consecutively for 48 h and the assessment on cell
ta represent mean value ± SE (n = 3).
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Reagents
MTT (3-(4,5-Dimethylthiazol-2-yl) -2,5-diphenyl tetra-
zolium bromide) and DMEM were purchased from Mo-
lecular Probes, Sigma and Gibco BRL, respectively.
Validated siRNAs against PLCG2 (Target sequenc 5'-
GACGACGGTTGTGAATGATAA-3') and CALM1(Tar-
get sequence 5'-CGGCAACTTACACACATTGAA-3')
were obtained from Qiagen. Upon delivery in the lyophi-
lized form, the siRNAs were diluted to obtain a 20 μM
solution using RNAse-free water and allocated into mul-
tiple reaction tubes for storage at -20o C as repeated
thawing might affect siRNA’s silencing efficiency.
Cell culture
HeLa cells were cultured in 25-cm2 flasks in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco BRL) sup-
plemented with 10% fetal bovine serum (FBS),
50 μg penicillin ml-1, 50 μg streptomycin ml-1 and
100 μg neomycin ml-1 at 37 °C in a humidified 5% CO2-
containing atmosphere.
Formation of siRNA/carbonate apatite complexes and
transfection of cells
Cells from the exponentially growth phase were seeded
at 50,000 cells per well into 24-well plates the day before
transfection. 3 μl of 1 M CaCl2 was mixed with 10 nM
of siRNA in 1 ml of fresh serum-free HCO3
- (44 mM)-
buffered DMEM medium (pH 7.5), followed by incuba-
tion at 37 °C for 30 min for complete generation of
siRNA/carbonate apatite particles [18,19]. 10% FBS and
(depending on the experimental conditions) 0.2 to 1 μM
drugs (cisplatin, doxorubicin, paclitaxel) had been mixed
with the medium containing the siRNA/apatite com-
plexes before the medium was added onto the rinsed
cells. The cells were subsequently cultured for 48 h prior
to the assessment on cell viability [18,19].
Cell viability assessment with MTT assay
30 μl of MTT solution (5 mg/ml) was added onto the
cells in each well of the 24-well plate and incubated for
4 hr at 37 °C. 0.5 ml of DMSO was added after removal
of the medium from each well to resolve the crystals,
followed by incubation for 5 min at 37 °C. Absorbance
was measured in a micro plate reader at 570 nm with
a reference wavelength of 630 nm. Each experiment
was done in triplicate with the data representing
mean value ± SE (n = 3) and being statistically significant
(< 0.05).
Abbreviations
PLCG2: PLC-gamma-2; CALM1: Calmodulin 1; PIP2: Phosphatidylinositol 4, 5
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